abstract |
A kind of bispecific recombinant protein comprises a high affinity tumor-targeting cancer and a low affinity fusion protein that blocks the interaction of CD47 with SIRPα, of which the antibody corresponding to the high affinity tumor-targeting cancer does not bind CD47, which is a tumor The binding affinity for the target antigen on the cell is at least 6 times that of the monomer fusion protein homodimer corresponding to the low affinity fusion protein that blocks the interaction of CD47 and SIRPα, and that of CD47 and SIRPα. Low-affinity fusion proteins that block interactions include SIRPα apoptotic entities. It further provides the use of said recombinant protein and nucleic acid molecule in the manufacture of a nucleic acid molecule encoding the recombinant protein and a drug for treating a tumor. |